TCRT - Alaunos Therapeutics, Inc.

2.76
0.030   1.087%

Share volume: 4,973
Last Updated: 04-23-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$2.73
0.03
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
38%
Profitability 35%
Dept financing 25%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.82%
1 Month
-12.10%
3 Months
-5.80%
6 Months
-2.13%
1 Year
2.99%
2 Year
133.90%
Key data
Stock price
$2.76
P/E Ratio 
0.00
DAY RANGE
$2.75 - $2.81
EPS 
-$2.56
52 WEEK RANGE
$1.67 - $6.20
52 WEEK CHANGE
$4.94
MARKET CAP 
5.290 M
YIELD 
N/A
SHARES OUTSTANDING 
2.232 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
2.23
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$14,822
AVERAGE 30 VOLUME 
$17,895
Company detail
CEO: Kevin S. Boyle
Region: US
Website: alaunos.com
Employees: 40
IPO year: 2006
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR. The company was formerly known as ZIOPHARM Oncology, Inc.

Recent news